News - Janssen

Filter

Current filters:

Janssen

Popular Filters

91 to 110 of 110 results

Janssen files NDA with FDA for canagliflozin in type 2 diabetes

01-06-2012

Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy

18-05-2012

Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results…

DiabetesJanssenJohnson & JohnsonNeurologicalNucyntaPharmaceuticalResearch

UK's NICE does U-turn, recommending Zytiga as Janssen cuts price

16-05-2012

UK drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has reversed an earlier…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Bristol-Myers expands hepatitis C accord with Medivir and Janssen

18-04-2012

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

News briefs on Janssen, Bayer and Merck KGaA/Threshold

12-04-2012

In the USA, the Arkansas jury found that the Janssen unit of US health care giant Johnson & Johnson (NYSE:…

BayerFinancialJanssenJohnson & JohnsonLegalMerck KGaAPharmaceuticalRegulationRisperdalThreshold PharmaceuticalsXarelto

Strong results for Bayer's Xarelto in treating pulmonary blood clots

27-03-2012

German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

Index Ventures debuts new Life Sciences Fund, partnered by GSK and J&J

21-03-2012

Index Ventures says it has launched its first fund solely dedicated to making investments in the life…

BiotechnologyFinancialGlaxoSmithKlineIndex VenturesJanssenJohnson & JohnsonPharmaceutical

Unblinded Zytiga study meets endpoints in prostate cancer

09-03-2012

Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), has…

JanssenJohnson & JohnsonOncologyPharmaceuticalResearchZytiga

Bayer and J&J’s Xarelto gets US Priority Review for new indication

29-02-2012

The US Food and Drug Administration has granted Priority Review designation to the supplemental New Drug…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Watson settles with Janssen over Ortho Tri-Cyclen LO

08-02-2012

US generic drugmaker Watson Pharmaceutical (NYSE: WPI) says that its subsidiary, Watson Laboratories,…

GenericsJanssenJohnson & JohnsonLegalNorth AmericaPatentsReproductiveWatson PharmaceuticalsWomen's Health

NICE issues negative guidance for Zytiga

02-02-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Janssen drops deal with Orexo for OX-CLI/OX-ESI

01-02-2012

US health care major Johnson & Johnson INYSE: JNJ) subsidiary Janssen has decided to end research collaboration…

FinancialJanssenJohnson & JohnsonLicensingOrexo ABPharmaceuticalRespiratory and Pulmonary

Germany’s IQWiG sees added benefits for Incivo

24-01-2012

In an early benefit assessment pursuant to Germany’s Act on the Reform of the Market for Medicinal…

Anti-viralsEuropeIncivekIncivoJanssenJohnson & JohnsonPharmaceuticalPricingRegulationVertex

Zytiga overtaking Provenge in MCRPC

17-01-2012

Despite no current approval of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Zytiga (abiraterone)…

BiotechnologyDendreonJanssenJevtanaJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeSanofiZytiga

Two UK product launches

16-01-2012

Danish drugmaker Lundbeck (LUND: DC) announced yesterday that Sycrest (asenapine) is being launched in…

Anti-viralsEuropeIntelenceJanssenJohnson & JohnsonLundbeckMarkets & MarketingNeurologicalPharmaceuticalSaphrisSycrest

91 to 110 of 110 results

Company Spotlight

Fibrotech

Fibrotech

Back to top